GlassScriptPhysician profile
Lauren Alysse Mitchell
NPI 1952785537
$994.36
in general payments reported to CMS, 2019-2025
17 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.25 · 2020: $33.64 · 2021: $33.40 · 2022: $76.34 · 2023: $226 · 2024: $327 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $233.62 | 2023-2025 | Airsupra, Farxiga |
| Amgen INC. | $167.46 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $115.66 | 2022-2025 | |
| Lilly USA, LLC | $65.63 | 2021-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.86 | 2023-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $58.50 | 2024-2025 | |
| Exact Sciences Corporation | $53.77 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $36.61 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $34.98 | 2020-2022 | |
| Novo Nordisk INC | $34.35 | 2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.96 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $28.88 | 2023 | Veozah, Myrbetriq |
| Tonix Medicines, INC. | $24.74 | 2025 | Tonmya |
| Biohaven Pharmaceutical Holding Company LTD. | $16.97 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.62 | 2025 | Qelbree |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $3.37 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.